S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
NASDAQ:ADAP

Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis

$1.16
-0.13 (-10.08%)
(As of 04/12/2024 08:50 PM ET)
Today's Range
$1.13
$1.28
50-Day Range
$1.15
$1.75
52-Week Range
$0.42
$2.05
Volume
3.08 million shs
Average Volume
1.81 million shs
Market Capitalization
$1.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Adaptimmune Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
331.0% Upside
$5.00 Price Target
Short Interest
Healthy
0.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Adaptimmune Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$12,855 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.44) to ($0.41) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.61 out of 5 stars

Medical Sector

654th out of 928 stocks

Biological Products, Except Diagnostic Industry

106th out of 147 stocks

ADAP stock logo

About Adaptimmune Therapeutics Stock (NASDAQ:ADAP)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

ADAP Stock Price History

ADAP Stock News Headlines

Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Down to $1.29
Elon Musk Secret Crypto Plot Exposed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Down 6.9%
Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Up to $1.35
Elon Musk Secret Crypto Plot Exposed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Peter W. Sonsini's Net Worth
ADAP Sep 2024 2.500 put
Adaptimmune Therapeutics Earnings Preview
Adaptimmune Therapeutics earnings: here's what Wall Street expects
ADAP Apr 2024 1.500 put
ADAP Apr 2024 2.000 call
See More Headlines
Receive ADAP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
4/14/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ADAP
Employees
449
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$10.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+331.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-113,870,000.00
Net Margins
-188.90%
Pretax Margin
-186.68%

Debt

Sales & Book Value

Annual Sales
$60.28 million
Book Value
$0.04 per share

Miscellaneous

Free Float
814,459,000
Market Cap
$1.15 billion
Optionable
Optionable
Beta
2.39
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives


ADAP Stock Analysis - Frequently Asked Questions

Should I buy or sell Adaptimmune Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ADAP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADAP, but not buy additional shares or sell existing shares.
View ADAP analyst ratings
or view top-rated stocks.

What is Adaptimmune Therapeutics' stock price target for 2024?

2 brokers have issued 12-month target prices for Adaptimmune Therapeutics' shares. Their ADAP share price targets range from $1.00 to $10.00. On average, they expect the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 331.0% from the stock's current price.
View analysts price targets for ADAP
or view top-rated stocks among Wall Street analysts.

How have ADAP shares performed in 2024?

Adaptimmune Therapeutics' stock was trading at $0.7930 at the beginning of 2024. Since then, ADAP shares have increased by 46.3% and is now trading at $1.16.
View the best growth stocks for 2024 here
.

When is Adaptimmune Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our ADAP earnings forecast
.

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) issued its earnings results on Wednesday, March, 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.12. The biotechnology company had revenue of $0.23 million for the quarter, compared to the consensus estimate of $4.80 million. Adaptimmune Therapeutics had a negative trailing twelve-month return on equity of 155.39% and a negative net margin of 188.90%.

What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO?

6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adaptimmune Therapeutics own?
When did Adaptimmune Therapeutics IPO?

Adaptimmune Therapeutics (ADAP) raised $150 million in an IPO on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADAP) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners